London, United Kingdom — New data reveals that over 100 deaths in the UK have been associated with popular weight-loss injections, raising significant concerns about the safety of these medications. Recent reports, compiled by the Medicines and Healthcare Products Regulatory Agency (MHRA), indicate that fatalities linked to drugs like Mounjaro and Ozempic are primarily occurring among users, including some young adults.
Two individuals in their 20s are among the deceased, as noted in an analysis of adverse event reports related to these medications. Of the 107 deaths recorded, the majority are tied to recently approved weight-loss treatments. In particular, Mounjaro, also known as tirzepatide, has been termed the “King Kong” of weight-loss jabs due to its perceived effectiveness in facilitating rapid weight loss, enabling users to drop significant body weight.
The MHRA has confirmed that at least ten of these deaths resulted from pancreatitis, a serious inflammation of the pancreas. This alarming trend has prompted officials to investigate whether genetic predispositions may contribute to the severity of this condition in certain patients. The agency’s announcement comes on the heels of a high-profile case involving a nurse in Scotland, who succumbed to organ failure and other complications attributed to Mounjaro after just two doses.
Medical professionals have voiced concern as a growing number of young women seek emergency care after using these drugs, often sourced through unregulated online pharmacies. Notably, many of these individuals do not present with obesity-related health issues and may use the injections for aesthetic goals.
Among the recorded deaths, liraglutide, marketed under the brand Saxenda, has been linked to 37 fatalities since its introduction in 2010. Both semaglutide—the active component in Ozempic and Wegovy—and tirzepatide have been associated with 30 deaths each, although Mounjaro’s rise to this figure occurred over a significantly shorter timeframe.
Experts are examining how these drugs may trigger pancreatitis, theorizing that they affect insulin regulation in the pancreas, potentially leading to excessive strain on the organ. The MHRA has received over 560 reports of pancreatitis linked to GLP-1 injections since their launch. To mitigate risks, health authorities are urging patients who experience adverse effects to report them using the Yellow Card scheme, enabling follow-up studies to identify vulnerable individuals.
In an effort to enhance patient safety, the MHRA is launching a new initiative aimed at developing a test to assess genetic risk factors for pancreatitis among potential users. This follows the recent easing of regulations surrounding access to weight-loss injections in England, now allowing general practitioners to prescribe Mounjaro more widely. Approximately 220,000 patients are expected to benefit from this expanded access over the next three years.
Although these weight-loss treatments are being promoted as tools to combat obesity, health officials caution that they are not without risks. Side effects commonly reported include gastrointestinal issues, and recent warnings highlight that Mounjaro could reduce the efficacy of oral contraceptive medications.
Manufacturers assure that patient safety remains a priority and emphasize ongoing monitoring of the drugs’ safety profiles. With nearly 200 deaths linked to similar medications in the United States, the global conversation surrounding the risks associated with weight-loss injections is intensifying, underscoring the need for vigilance among users and healthcare providers alike.